Different effects of desipramine on bufuralol 1″-hydroxylation by rat and human CYP2D enzymes

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 4, 2005, Pages 634-640

  Isobe, Takashi ^a   Hichiya, Hiroyuki ^a   Hanioka, Nobumitsu ^a   Yamamoto, Shigeo ^a   Shinoda, Sumio ^a   Funae, Yoshihiko ^b   Satoh, Tetsuo ^c   Yamano, Shigeru ^d   Narimatsu, Shizuo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Human Animal Bridge Discussion Group   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

Binding; CYP2D2; CYP2D6; Desipramine; Inactivation; Reactive metabolite

Indexed keywords

BUFURALOL; CYTOCHROME P450 2D; CYTOCHROME P450 2D1; CYTOCHROME P450 2D2; CYTOCHROME P450 2D6; DESIPRAMINE; IMIPRAMINE; PROPRANOLOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; COVALENT BOND; DRUG HYDROXYLATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARYL HYDROCARBON HYDROXYLASES; DESIPRAMINE; ETHANOLAMINES; HUMANS; HYDROXYLATION; IMIPRAMINE; KINETICS; MALE; MICROSOMES, LIVER; MIDDLE AGED; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

EID: 21144437731     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.634     Document Type: Article

References (17)

1. Sallee F. R., Pollock B. G., Clin. Pharmacokinet., 18, 346-364 (1990).
2. Koyama E., Chiba K., Tani M., Ishizaki T., J. Pharmacol. Exp. Ther., 281, 1199-1210 (1997).
3. Madsen H., Rasmussen B., Brosen K., Clin. Pharmacol. Ther., 61, 319-324 (1997).
4. Breyer U., Naunyn-Schmiedebergs Arch. Pharmacol., 272, 277-288 (1972).
5. Daniel W., Friebertshauser J., Steffen C., Naunyn-Schmiedebergs Arch. Pharmacol., 328, 83-86 (1984).
6. Daniel W., Netter J., Naunyn-Schmiedebergs Arch. Pharmacol., 342, 234-240 (1990).
7. Masubuchi Y., Takahashi C., Fujio N., Horie T., Suzuki T., Imaoka S., Funae Y., Narimatsu S., Drug Metab. Dispos., 23, 999-1003 (1995).
8. Masubuchi Y., Igarashi S., Suzuki T., Horie T., Narimatsu S., J. Pharmacol Exp. Ther., 279, 724-731 (1996).
9. Wan J., Imaoka S., Chow T., Hiroi T., Yabusaki Y., Funae Y., Arch. Biochem. Biophys., 348, 383-390 (1997).
10. Omura T., Sato R., J. Biol. Chem., 239, 2370-2378 (1964).
11. Tsuzuki D., Takemi C., Yamamoto S., Tamagake K., Imaoka S., Funae Y., Kataoka H., Shinoda S., Narimatsu S., Pharmacogenetics, 11, 709-718 (2001).
12. Narimatsu S., Imoto K., Isobe T., Kiryu K., Naito S., Hichiya H., Funae Y., Hanioka N., Yamamoto S., Biochem. Biophys. Res. Commun., 324, 627-633 (2004).
13. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmacobio-Dyn., 4, 879-885 (1981).
14. Silverman R. B., "Chemistry and Enzymology," Vol. 1, CRC Press, Boca Raton, FL, 1988, pp. 3-30.
15. Guengerich F. P., Wang P., Davidson N. K., Biochemistry, 21, 1698-1706 (1982).
16. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., J. Biol. Chem., 193, 265-275 (1951).
17. Hiroi T., Imaoka S., Chow T., Funae Y., Biochim. Biophys. Acta, 1380, 305-312 (1998).